A retrospective cohort study of ustekinumab or vedolizumab in patients with inflammatory bowel disease (IBD)
Latest Information Update: 15 Dec 2022
At a glance
- Drugs Ustekinumab (Primary) ; Vedolizumab (Primary) ; Immunomodulators; Immunosuppressants; Tumour necrosis factor inhibitors
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- 15 Dec 2022 New trial record
- 01 Dec 2022 Results published in the Inflammatory Bowel Diseases